CLL
Supportive Care and Other Tools for Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In patients who received prior chronic lymphocytic leukemia/small lymphocytic lymphoma-directed therapy but require ...
MARCH 10, 2025
Paving the Way for First-Line Oral Doublet in CLL
An all-oral combination of the BTK inhibitor acalabrutinib (Calquence, AstraZeneca) and the BCL-2 inhibitor ...
JANUARY 29, 2025
Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic lymphocytic leukemia is a lymphoproliferative disorder characterized by the accumulation of circulating ...
APRIL 10, 2024
Measurable Residual Disease Testing in the Community Oncology Setting
In the game of chess, anticipating the correct response to each of your opponent’s moves on the board can ...
FEBRUARY 7, 2024
FDA Withdraws Umbralisib Due to Elevated Mortality Risk
The FDA announced that it has withdrawn approval for umbralisib (Ukoniq, TG Therapeutics), based on an updated ...
JUNE 3, 2022
New CLL Data Point to ‘Durable, Lasting Response’
Aseries of studies and trials conducted in chronic lymphocytic leukemia suggest that an increasing proportion of ...
OCTOBER 12, 2021
More Specific BTK Inhibitor Shows High Relative Rates of Response in CLL
ORLANDO, FLA.—In a phase 3 trial, acalabrutinib, a second-generation Bruton’s tyrosine kinase (BTK), ...
JANUARY 27, 2020
Study Identifies Cardiovascular Toxicities Associated With Ibrutinib
The study identified several cardiovascular toxicities associated with ibrutinib, including supraventricular ...
SEPTEMBER 26, 2019
Ibrutinib Bests Drug Combo in Older CLL Pts
San Diego—In older patients with newly diagnosed chronic lymphocytic leukemia (CLL), the BTK inhibitor ...
MARCH 4, 2019
First-Line Ibrutinib-Based Rx More Effective, Less Toxic Than Standard for Younger CLL Patients
First-line treatment combining ibrutinib and rituximab (significantly improves progression-free survival and ...
JANUARY 14, 2019
FDA Approves Copiktra for Relapsed or Refractory CLL, SLL
Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of ...
SEPTEMBER 29, 2018
Venclexta Approved for CLL/SLL After 1 Prior Therapy
The FDA granted regular approval to venetoclax (Venclexta, AbbVie/Genentech) in patients with chronic ...
JUNE 18, 2018
